Before targeted therapies like trastuzumab, patients with HER2-positive lung cancer had limited options apart from standard chemotherapy, with generally poor outcomes and greater side effects.

Study shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. In patient samples of lung adenocarcinoma, 3 percent were found to have HER2 ...

HER2-positive metastatic breast cancer, an aggressive disease characterized by overexpression or amplification of HER2, occurs in approximately 15% to 20% of patients with metastatic breast cancer.